Leisa K Johnson

US Patent:

7078030, Jul 18, 2006

Filed:

Dec 11, 2003

Appl. No.:

10/733674

Inventors:

Leisa Johnson - Richmond CA, US
Ali Fattaey - Oakland CA, US
Terry Hermiston - Corte Madera CA, US
Jerry Yuqiao Shen - Orinda CA, US
Sylvie Laquerre - Conshohocken PA, US

Assignee:

Onyx Pharmaceuticals, Inc - Emeryville CA

International Classification:

A61K 48/00
C12N 15/00
C12N 15/63
C12N 5/00
C12N 15/86

US Classification:

424 932, 4353201, 435325, 435457

Abstract:

Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.

US Patent:

7396679, Jul 8, 2008

Filed:

Nov 25, 2002

Appl. No.:

10/303598

Inventors:

Leisa Johnson - Lafayette CA, US
Ali Fattaey - San Francisco CA, US
Terry Hermiston - Corte Madera CA, US
Yuqiao Shen - Orinda CA, US
Sylvie Laquerre - Conshohocken PA, US

Assignee:

Onyx Pharmaceuticals, Inc. - Emeryville CA

International Classification:

C12N 15/00

US Classification:

4353201

Abstract:

Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.

US Patent:

7829329, Nov 9, 2010

Filed:

Nov 27, 2002

Appl. No.:

10/306275

Inventors:

Terry Hermiston - Corte Madera CA, US
Lynda K. Hawkins - Germantown MD, US
Leisa Johnson - Richmond CA, US

Assignee:

Onyx Pharmaceuticals, Inc. - Emeryville CA

International Classification:

C12N 15/00
C12N 7/00
A01N 43/04

US Classification:

4353201, 4352351, 514 44 R

Abstract:

Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous adenoviral transcriptional control sequences will exhibit an expression pattern, both in terms of timing and degree of expression, similar to the endogenous adenoviral gene(s) that it replaces, and further optionally including mutations in other parts of the adenoviral genome, including certain E1B or E1A regions, and that have applications for diagnosing or treating disease, preferably disease involving unwanted cell growth, including cancer.

US Patent:

8247397, Aug 21, 2012

Filed:

Sep 10, 2008

Appl. No.:

12/208227

Inventors:

Marcia Belvin - South San Francisco CA, US
Lori Friedman - South San Francisco CA, US
Klaus Hoeflich - San Mateo CA, US
Deepak Sampath - San Francisco CA, US
Ulka Vijapurkar - Millbrae CA, US
Jeffrey Wallin - Berkeley CA, US
Leisa Johnson - Point Richmond CA, US
Mallika Singh - San Francisco CA, US
Sonal Patel - Slough, GB

Assignee:

Genentech, Inc. - South San Francisco CA
F. Hoffman-La Roche AG - Basel

International Classification:

A61K 31/33

US Classification:

514183

Abstract:

Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

US Patent:

8604014, Dec 10, 2013

Filed:

May 17, 2011

Appl. No.:

13/109670

Inventors:

Marcia Belvin - South San Francisco CA, US
Lori Friedman - South San Francisco CA, US
Klaus Hoeflich - South San Francisco CA, US
Deepak Sampath - South San Francisco CA, US
Ulka Vijapurkar - South San Francisco CA, US
Jeffrey Wallin - South San Francisco CA, US
Leisa Johnson - South San Francisco CA, US
Mallika Singh - South San Francisco CA, US
Sonal Patel - Basel, GB

Assignee:

Genentech, Inc. - South San Francisco CA
F. Hoffmann-La Roche AG - Basel

International Classification:

A61K 31/33
G01N 33/00

US Classification:

514183, 436 91

Abstract:

Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

US Patent:

20060257370, Nov 16, 2006

Filed:

Jul 17, 2006

Appl. No.:

11/488533

Inventors:

Terry Hermiston - Corte Madera CA, US
Lynda Hawkins - Germantown MD, US
Leisa Johnson - Richmond CA, US

Assignee:

Onyx Pharmaceuticals - Emeryville CA

International Classification:

A61K 48/00
C12N 5/08
C12N 15/861

US Classification:

424093200, 435456000, 435366000

Abstract:

Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous adenoviral transcriptional control sequences will exhibit an expression pattern, both in terms of timing and degree of expression, similar to the endogenous adenoviral gene(s) that it replaces, and further optionally including mutations in other parts of the adenoviral genome, including certain E1B or E1A regions, and that have applications for diagnosing or treating disease, preferably disease involving unwanted cell growth, including cancer.

US Patent:

20060257371, Nov 16, 2006

Filed:

Jul 17, 2006

Appl. No.:

11/488534

Inventors:

Terry Hermiston - Corte Madera CA, US
Lynda Hawkins - Germantown MD, US
Leisa Johnson - Richmond CA, US

Assignee:

Onyx Pharmaceuticals - Emeryville CA

International Classification:

A61K 48/00
C12N 5/08
C12N 15/861

US Classification:

424093200, 435456000, 435366000

Abstract:

Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous adenoviral transcriptional control sequences will exhibit an expression pattern, both in terms of timing and degree of expression, similar to the endogenous adenoviral gene(s) that it replaces, and further optionally including mutations in other parts of the adenoviral genome, including certain E1B or E1A regions, and that have applications for diagnosing or treating disease, preferably disease involving unwanted cell growth, including cancer.

US Patent:

20060292122, Dec 28, 2006

Filed:

Jul 17, 2006

Appl. No.:

11/488543

Inventors:

Terry Hermiston - Corte Madera CA, US
Lynda Hawkins - Germantown MD, US
Leisa Johnson - Richmond CA, US

Assignee:

Onyx Pharmaceuticals - Emeryville CA

International Classification:

A61K 48/00
C12N 15/867

US Classification:

424093200, 435456000

Abstract:

Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous adenoviral transcriptional control sequences will exhibit an expression pattern, both in terms of timing and degree of expression, similar to the endogenous adenoviral gene(s) that it replaces, and further optionally including mutations in other parts of the adenoviral genome, including certain E1B or E1A regions, and that have applications for diagnosing or treating disease, preferably disease involving unwanted cell growth, including cancer.